New depression pill shows promise in early trial
NCT ID NCT03726658
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested an experimental drug called AGN-241751 in 226 adults with major depressive disorder. Participants received either the drug or a placebo to see if it could quickly improve depression symptoms. The trial was completed and aimed to measure changes in mood using a standard depression scale.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AGN-241751 (an experimental oral drug for depression)
What this could lead to
If successful, this could point toward a new, fast-acting treatment option for people with major depressive disorder.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so results may not confirm effectiveness or safety. The drug may not work better than placebo or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alea Research
Phoenix, Arizona, 85012, United States
-
Atlanta Center for Medical Research
Atlanta, Georgia, 30331, United States
-
Collaborative Neuroscience Network, LLC
Garden Grove, California, 92845, United States
-
Hassman Research Institute
Berlin, New Jersey, 08809, United States
-
Northwest Clinical Research Center
Bellevue, Washington, 98007, United States